Related Experiment Video
Updated: May 14, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
Management of the new patient with CML in chronic phase
1Department of Haematology, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK. d.marin@imperial.ac.uk
Abstract:
Imatinib has been the preferred initial therapy for newly diagnosed chronic myeloid leukemia (CML) patients for the last 10 years. Today, other tyrosine kinase inhibitors (TKIs) are licensed for first-line use. In this paper we analyze the pros and cons of the various alternatives to imatinib and try to give some advice on the management of the newly diagnosed patient.
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Myocarditis IV: Nursing Management
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Differentiation of Common Myeloid Progenitor Cells
Chronic Obstructive Pulmonary Disease-V: Nursing Management
Assessment
Chronic Kidney Disease IV: Nursing Management
